DEF: Harvard Bioscience 2026 Annual Meeting Proxy

Harvard Bioscience schedules its 2026 Annual Meeting of Stockholders for June 2, 2026, to vote on director elections, executive compensation, and equity plan amendments.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for June 2, 2026, at 10:00 a.m. ET via virtual-only format.
• The record date for voting is April 7, 2026, with 4,510,217 shares of common stock outstanding.
• Proposals include the election of two Class II Directors, ratification of Grant Thornton LLP as auditors, advisory vote on executive compensation, and amendments to the Employee Stock Purchase Plan (ESPP) and 2021 Incentive Plan.
• The ESPP amendment seeks to authorize an additional 120,000 shares.
• The 2021 Incentive Plan amendment seeks to authorize an additional 400,000 shares.
• A 10:1 reverse stock split was completed on March 13, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a defensive filing, reflecting a company struggling with profitability and high debt, attempting to stabilize its equity incentive structure.

Positives

• Successful refinancing of the company's credit facility in December 2025.
• Implementation of a Dodd-Frank compliant clawback policy.
• Executive stock ownership guidelines are in place, with all named executive officers in compliance as of December 31, 2025.
• The company has transitioned to a virtual meeting format to reduce costs and environmental impact.

Negatives

• The company reported a net loss of $56.7 million for the fiscal year 2025.
• No payouts were made under the 2025 Annual Cash Incentive Plan due to failure to meet performance thresholds.
• The company's stock price experienced a significant year-over-year decrease from 2023 to 2024.
• The company is heavily reliant on debt financing, with a new $40 million term loan agreement entered into in December 2025.

Risks

• Potential for future dilution of shareholder value due to the requested increases in authorized shares for equity plans.
• High interest rate obligations associated with the new term loans (12.80% initially).
• Dependence on the successful execution of strategic growth and operational excellence initiatives.
• Risks associated with the company's ability to meet financial covenants in the new loan agreement.

Future Outlook

Management is focused on driving growth and operational excellence, with executive compensation tied to relative total shareholder return (TSR) and organic revenue growth targets.

Management Comments

• The Board believes that increasing the total number of authorized shares for issuance under the ESPP and 2021 Incentive Plan is necessary to retain employees with a market-competitive benefit.
• The Board believes that equity incentives are a significant factor in attracting and motivating eligible persons whose contributions are important to the company.

Industry Context

StockSavvy.ai notes that Harvard Bioscience is navigating a challenging environment for life science tools companies, characterized by high debt costs and the need to incentivize talent despite significant net losses and stock price volatility.

Comparison to Industry Standards

• The company's use of relative TSR for performance-based RSU vesting is consistent with modern corporate governance practices among small-cap life science firms.
• The 10:1 reverse stock split is a common defensive measure for companies facing Nasdaq listing compliance issues regarding minimum bid prices.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• The company entered into a $40 million Loan and Security Agreement with BroadOak Income Fund and BroadOak Fund VI in December 2025, where William Snider (a Director) is a manager.

Stakeholder Impact

• Shareholders face potential dilution from the proposed increase in authorized shares.
• Employees may benefit from the expanded equity incentive and stock purchase opportunities.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 2, 2026.
• Execute the proposed amendments to the ESPP and 2021 Incentive Plan if approved by shareholders.
• Continue monitoring compliance with the new loan agreement covenants.

Key Dates

Recommendation

The company is in a turnaround phase with significant debt and recent leadership changes; investors should wait for evidence of improved operational performance before increasing exposure.

Keywords

Harvard Bioscience, HBIO, Proxy Statement, Annual Meeting, Executive Compensation, Equity Incentive Plan, Corporate Governance